Syndax's CEO talks about the company's two new launches (Revuforj and Niktimvo), both of which are tracking ahead of expectations
- Sep 8, 2025
- 1 min read
Michael Metzger describes the uptake of the therapies, both of which were approved in the second half of last year, and highlights a potential new indication (NPM1 mutations) for Revuforj that is in front of FDA right now. Plus, how investors should think about Syndax over the year ahead.
Coverage brought to you by:
.png){kind=logo}